Your browser doesn't support javascript.
loading
Cost-effectiveness of Adjuvant Pembrolizumab After Nephrectomy for High-risk Renal Cell Carcinoma: Insights for Patient Selection From a Markov Model.
Sharma, Vidit; Wymer, Kevin M; Joyce, Daniel D; Moriarty, James; Khanna, Abhinav; Borah, Bijan J; Thompson, R Houston; Costello, Brian A; Leibovich, Bradley C; Boorjian, Stephen A.
Afiliación
  • Sharma V; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Wymer KM; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Joyce DD; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Moriarty J; Department of Health Services Research, Mayo Clinic, Rochester, Minnesota.
  • Khanna A; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Borah BJ; Department of Health Services Research, Mayo Clinic, Rochester, Minnesota.
  • Thompson RH; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Costello BA; Department of Oncology, Mayo Clinic, Rochester, Minnesota.
  • Leibovich BC; Department of Urology, Mayo Clinic, Rochester, Minnesota.
  • Boorjian SA; Department of Urology, Mayo Clinic, Rochester, Minnesota.
J Urol ; 209(1): 89-98, 2023 01.
Article en En | MEDLINE | ID: mdl-36067373

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans País/Región como asunto: America do norte Idioma: En Revista: J Urol Año: 2023 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Carcinoma de Células Renales / Neoplasias Renales Tipo de estudio: Etiology_studies / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Límite: Aged / Humans País/Región como asunto: America do norte Idioma: En Revista: J Urol Año: 2023 Tipo del documento: Article